“…SLC18A2, also known as VMAT2, is responsible for transporting monoamine neurotransmitters (serotonin, noradrenaline, dopamine) into synaptic vesicles (Erickson et al, 1996). It has been implicated in several complex disorders including Parkinson's disease (Sala et al, 2010), depression (Christiansen et al, 2007), alcohol, and nicotine dependence (Schwab et al, 2005), prostate cancer (Sorensen et al, 2009), and Tourette's syndrome (Ben-Dor et al, 2007). SLC18A2 is also the target of reserpine and tetrabenazine (Peter et al, 1993), drugs used to treat high blood pressure, agitation, tardive dyskinesia, and involuntary movements of Huntington's disease.…”